A Phase II Clinical Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors
Phase of Trial: Phase II
Latest Information Update: 14 Jul 2017
At a glance
- Drugs Amcasertib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- Sponsors Boston Biomedical
- 10 Jun 2017 Biomarkers information updated
- 25 Mar 2017 Status changed from not yet recruiting to recruiting.
- 13 Sep 2016 Planned primary completion date changed from 1 Jul 2017 to 1 Dec 2018.